Alternatives to the Adlyxin Starter Kit If You Can't Fill Your Prescription

The Adlyxin Starter Kit (lixisenatide) was permanently discontinued in the United States in January 2023. If you were relying on lixisenatide to manage your type 2 diabetes, you are not alone in needing a replacement. The good news: the GLP-1 receptor agonist class is rich with effective alternatives, several of which may outperform lixisenatide based on current clinical evidence.

This guide walks through the most relevant alternatives — what they are, how they compare, and how to talk to your doctor about making the switch.

Option 1: Soliqua 100/33 (Insulin Glargine + Lixisenatide) — Still Available in the US

If the reason lixisenatide worked for you was its postprandial glucose control and you also need basal insulin, Soliqua 100/33 is the closest available option. It combines insulin glargine (Lantus) with lixisenatide in a single pen, providing both basal and prandial glycemic coverage. Soliqua is specifically indicated for adults with type 2 diabetes inadequately controlled on basal insulin (less than 60 units daily) or lixisenatide alone.

Key considerations for Soliqua:

Contains lixisenatide — the same active GLP-1 ingredient as Adlyxin

Once-daily injection with the first meal of the day

Not appropriate for patients who do not need insulin

Requires insulin titration protocols and close glucose monitoring

Option 2: Semaglutide (Ozempic) — The Most Prescribed GLP-1 in 2026

Ozempic (semaglutide) is a once-weekly injectable GLP-1 receptor agonist approved for type 2 diabetes. It delivers significantly stronger A1C reduction than lixisenatide — on average 1.0 to 1.8% — and is associated with meaningful weight loss of 3 to 6 kg in diabetes-focused trials. Ozempic also has proven cardiovascular benefits, reducing the risk of major adverse cardiovascular events in patients with established heart disease.

Why patients switch to Ozempic from Adlyxin:

Once-weekly dosing versus once-daily, reducing injection burden

Greater A1C reduction and weight loss

Cardiovascular outcome data supporting use in high-risk patients

Widely available at most US pharmacies (though some doses face intermittent stock issues)

Option 3: Dulaglutide (Trulicity) — Weekly Injection, Easy Auto-Injector

Trulicity (dulaglutide) is a once-weekly GLP-1 receptor agonist that has been on the market since 2014. It delivers comparable A1C reduction to semaglutide at lower doses and is available in a ready-to-use single-dose auto-injector with a hidden needle — often preferred by patients who are needle-averse. Trulicity also has cardiovascular outcome data and is available in doses from 0.75 mg to 4.5 mg weekly.

Trulicity may be preferred for:

Patients new to injections who prefer a hidden-needle auto-injector

Patients with cardiovascular disease or multiple risk factors who want proven heart outcomes data

Patients who prefer no meal-timing requirement (can inject any time of day)

Option 4: Liraglutide (Victoza) — Closest Daily Injection Alternative

Victoza (liraglutide) is the most similar replacement in terms of dosing frequency — it is also a once-daily injectable GLP-1 agonist. Liraglutide was the first long-acting GLP-1 analog on the US market (2010) and has an extensive safety and efficacy record. It reduces A1C by approximately 1.0 to 1.5% and promotes modest weight loss. Victoza also has proven cardiovascular benefit (LEADER trial) in patients with established cardiovascular disease.

Victoza may be preferred for:

Patients who prefer to keep a daily injection schedule

Patients with established cardiovascular disease who need proven outcomes data

Patients who tolerated daily GLP-1 injections well and do not want to change frequency

Option 5: Tirzepatide (Mounjaro) — Dual GIP/GLP-1 Agonist for Maximum Efficacy

Mounjaro (tirzepatide) is a once-weekly dual GIP and GLP-1 receptor agonist approved for type 2 diabetes. It represents the most efficacious diabetes agent in the incretin class, achieving A1C reductions of 1.8 to 2.4% and weight loss of 5 to 11 kg in clinical trials — significantly outperforming any single GLP-1 agonist including lixisenatide. It is a strong option for patients who were not achieving A1C targets on lixisenatide alone.

Comparing the Options at a Glance

Soliqua 100/33: Daily injection; contains lixisenatide; requires basal insulin need; still available

Ozempic (semaglutide): Weekly injection; strong A1C/weight effect; cardiovascular benefit; most-prescribed GLP-1

Trulicity (dulaglutide): Weekly auto-injector; hidden needle; cardiovascular outcomes data; multiple doses

Victoza (liraglutide): Daily injection; long safety record; cardiovascular benefit; closest frequency to Adlyxin

Mounjaro (tirzepatide): Weekly dual agonist; highest A1C reduction and weight loss in class

Finding Your Replacement Medication in Stock

Once your doctor prescribes an alternative, locating it at a pharmacy near you can still be a challenge — especially for medications like Ozempic that have faced intermittent supply issues. medfinder can call pharmacies in your area on your behalf to find which ones have your specific GLP-1 medication and dose in stock. See also our guide on how to find GLP-1 medications near you for more tips.